Please assess the completion status of the following clinical trial:

Trial Title: Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Both male and female adult patients with a history of Season Allergic Rhinitis (SAR) with bothersome symptoms due to Mountain Cedar pollinosis confirmed using the Modified Quantitate Test (MQT; defined as a wheal greater than or equal to 3 millimeters larger than the diluent control)~2. Patients must be willing to provide written, informed consent~3. Patients must be willing and able to comply with study procedures~4. Women of childbearing potential must agree to use an acceptable form of contraception during the trial~Exclusion Criteria:~1. Patients less than 18 years of age~2. Clinically-significant chronic sinusitis, as determined by the investigator~3. History of anaphylaxis during Mountain Cedar skin prick testing~4. Participation in another clinical trial or use of an experimental medication within 30 days of enrollment~5. Medically significant co-morbidities that, in the opinion of the investigator, place the subject at increased risk during the study, including but not limited to:~   1. Autoimmune diseases, other than allergic rhinitis (AR), stable allergic asthma, eczema and food sensitivities~  2. Pulmonary or respiratory diseases other than stable asthma~  3. Cancer other than basal cell carcinoma~  4. Coronary artery disease or hypertension treated with beta-blockers~  5. Clinically significant impairment of renal or hepatic function~6. Use of concomitant medications that, in the opinion of the investigator, may reduce the effectiveness of rescue treatments for anaphylaxis (e.g. beta-blockers) or alter the immune response to allergen immunotherapy (e.g., immunosuppressants, systemic corticosteroids)~7. Previously completed immunotherapy for Mountain Cedar pollinosis, that in the opinion of the investigator would interfere with the assessment or treatment of the patient~8. Inability to access suitable lymph nodes for intralympahtic injections~9. Plans to leave the area for a significant period of the upcoming Mountain Cedar pollen season~10. Pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intra-lymphatic allergenic extract (Type: EXPERIMENTAL): A series of three injections of 0.1 mL (about 2 drops) of the allergenic extract of Mountain Cedar Pollen given every four weeks into a superficial inguinal lymph node through guidance via ultrasonography using a 1-mL hypodermic syringe with a 25-gauge or smaller needle.
- Intra-lymphatic placebo (Type: PLACEBO_COMPARATOR): Diluent as placebo control (sterile saline solution containing 0.4% phenol as a preservative and matched concentration of glycerin) given as a series of three injections of 0.1 mL (about 2 drops) every four weeks into a superficial inguinal lymph node through guidance via ultrasonography using a 1-mL hypodermic syringe with a 25-gauge or smaller needle.

Based on this trial design, predict the completion outcome and termination type (if applicable).